| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA382433
Max Phase: Preclinical
Molecular Formula: C20H18N6O2S5
Molecular Weight: 534.74
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: O=S(=O)(NC1=NCCN1C(=S)SN1CCn2c1nsc2=S)c1ccc(-c2ccccc2)cc1
Standard InChI: InChI=1S/C20H18N6O2S5/c27-33(28,16-8-6-15(7-9-16)14-4-2-1-3-5-14)23-17-21-10-11-24(17)20(30)32-26-13-12-25-18(26)22-31-19(25)29/h1-9H,10-13H2,(H,21,23)
Standard InChI Key: IZHDQJFUWYIVLR-UHFFFAOYSA-N
Associated Targets(Human)
KYSE-510 286 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 534.74 | Molecular Weight (Monoisotopic): 534.0095 | AlogP: 3.74 | #Rotatable Bonds: 4 |
| Polar Surface Area: 82.83 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 1 |
| #RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 9.77 | CX Basic pKa: 0.99 | CX LogP: 5.41 | CX LogD: 5.41 |
| Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.40 | Np Likeness Score: -1.34 |
References
| 1. Saczewski J, Brzozowski Z, Saczewski F, Bednarski PJ, Liebeke M, Gdaniec M.. (2006) Synthesis and in vitro anti-tumor activity of N-{1-[(3-thioxo-5,6-dihydroimidazo[2,1-c][1,2,4]thiadiazol-7-ylthio)thiocarbonyl]-2-imidazolidene}arylsulfonamides., 16 (14): [PMID:16682194] [10.1016/j.bmcl.2006.04.067] |
Source
Source(1):